Takeda oncology demonstrates leadership in hematologic cancers at 62nd american society of hematology (ash) annual meeting

Cambridge, mass. & osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that it will present 22 company-sponsored abstracts at the 62nd american society of hematology (ash) annual meeting, being held virtually december 5-8, 2020. the company's scientific research at ash will identify unique approaches in advancing the treatment of hematologic cancers, illustrative of its commitment to developing and providing transformative solution
TAK Ratings Summary
TAK Quant Ranking